[go: up one dir, main page]

AR042628A1 - Derivados de piperidina como moduladores del receptor ccr5 - Google Patents

Derivados de piperidina como moduladores del receptor ccr5

Info

Publication number
AR042628A1
AR042628A1 ARP030104682A ARP030104682A AR042628A1 AR 042628 A1 AR042628 A1 AR 042628A1 AR P030104682 A ARP030104682 A AR P030104682A AR P030104682 A ARP030104682 A AR P030104682A AR 042628 A1 AR042628 A1 AR 042628A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
heteroaryl
halo
phenyl
Prior art date
Application number
ARP030104682A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0203821A external-priority patent/SE0203821D0/xx
Priority claimed from SE0300499A external-priority patent/SE0300499D0/xx
Priority claimed from SE0301425A external-priority patent/SE0301425D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR042628A1 publication Critical patent/AR042628A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Procesos para su preparación y su uso en terapia medicinal (por ejemplo la modulación de la actividad receptora de CCR5 en un animal de sangre caliente). Reivindicación 1: Un compuesto de fórmula (1), en la cual: A está ausente o es (CH2)2; R1 es alquilo C1-8, C(O)NR10R11, C(O)2R12, NR13C(O)R14, NR15C(O)NR16R17, NR18C(O)R19, heterociclilo, arilo o heteroarilo; R10, R13, R15, R16 y R18 son hidrógeno o alquilo C1-6; R11, R12, R14, R17 y R19 son alquilo C1-8 (sustituido opcionalmente con halo, hidroxi, alcoxi C1-6, haloalcoxi C1-6, cicloalquilo C3-6 (sustituido opcionalmente con halo),cicloalquilo C5-6, S(alquilo C1-4), S(O)(alquilo C1-4), S(O)2(alquilo C1-4), heteroarilo, arilo, heteroariloxi o ariloxi), arilo, heteroarilo, cicloalquilo C3-7 (sustituido opcionalmente con halo o alquilo C1-4), cicloalquilo C4-7 fusionado a un anillo fenilo, cicloalquenilo C5-7, o heterociclilo (sustituido en sí mismo con oxo, C(O)(alquilo C1-6), S(O)k(alquilo C1-6), halo o alquilo C1-4); o R11, R12, R14 y R17 también pueden ser hidrógeno; o R10 y R11, y/o R16 y R17 se pueden unir para formar un anillo de 4, 5 ó 6 miembros que incluye opcionalmente un átomo de nitrógeno, oxígeno o azufre, donde dicho anillo está sustituido opcionalmente con alquilo C1-6, S(O)1(alquilo C1-6) o C(O)(alquilo C1-6); R2 es alquilo C1-6, fenilo, heteroarilo o cicloalquilo C3-7; R3 es H o alquilo C1-4; R4 es arilo, heteroarilo, alquilo C1-6 o cicloalquilo C3-7; X es O o S(O)p; m y n son, independientemente, 0, 1, 2 ó 3, siempre que m + n sea 1 ó más; los restos arilo, fenilo y heteroarilo están independientemente sustituidos de manera opcional con uno o más de halo, ciano, nitro, hidroxi, OC(O)NR20R21, NR22R23, NR24C(O)R25, NR26C(O)NR27R28, S(O)2NR29R30, NR31S(O)2R32, C(O)NR33R34, CO2R36, NR37CO2R38, S(O)qR39, OS(O)2R49 alquilo C1-6 (mono sustituido opcionalmente con S(O)2R50 o C(O)NR51R52), alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-10, haloalquilo C1-6, alcoxi(C1-6)-alquilo(C1-6), alcoxi C1-6 (opcionalmente mono sustituido con CO2R53, C(O)NR54R55, ciano, heteroarilo o C(O)NHS(O)2R56), NHC(O)NHR57, haloalcoxi C1-6, fenilo, fenilalquilo (C1-4), fenoxi, feniltio, fenilS(O), fenilS(O)2, fenilalcoxi (C1-4), heteroarilo, heteroarilalquilo (C1-4), heteroariloxi o heteroarilalcoxi (C1-4), en los cuales cualquiera de los restos fenilo y heteroarilo inmediatamente precedentes están sustituidos opcionalmente con halo, hidroxi, nitro, S(alquilo C1-4), S(O)(alquilo C1-4), S(O)2(alquilo C1-4), S(O)2NH2, S(O)2NH(alquilo C1-4), S(O)2N(alquilo C1-4)2, ciano, alquilo C1-4, alcoxi C1-4, C(O)NH2, C(O)NH(alquilo C1-4), C(O)N(alquilo C1-4)2, CO2H, CO2(alquilo C1-4), NHC(O)(alquilo C1-4), NHS(O)2(alquilo C1-4), CF3 o OCF3; salvo que se especifique lo contrario, heterociclilo está sustituido de manera opcional con alquilo C1-6 [sustituido opcionalmente con fenilo {que en sí mismo se sustituye de manera opcional con halo, alquilo C1-4, alcoxi C1-4, ciano, nitro, CF3, OCF3, (alquil C1-4)C(O)NH, S(O)2NH2, alquiltio C1-4, S(O)(alquilo C1-4) o S(O)2(alquilo C1-4)} o heteroarilo {que en sí mismo se sustituye opcionalmente con halo, alquilo C1-4, alcoxi C1-4, ciano, nitro, CF3, (alquil C1-4)C(O)NH, S(O)2NH2, alquiltio C1-4, S(O)(alquilo C1-4) o S(O)2(alquilo C1-4)}], fenilo {sustituido opcionalmente con halo, alquilo C1-4, alcoxi C1-4, ciano, nitro, CF3, OCF3, (alquil C1-4)C(O)NH, S(O)2NH2, alquiltio C1-4, S(O)(alquilo C1-4) o S(O)2(alquilo C1-4)} o heteroarilo {opcionalmente sustituido con halo, alquilo C1-4, alcoxi C1-4, ciano, nitro, CF3, (alquil C1-4)C(O)NH, S(O)2NH2, alquiltio C1-4, S(O)(alquilo C1-4) o S(O)2(alquilo C1-4)}, S(O)2NR40R41, C(O)R42, C(O)2(alquilo C1-6) (tal como tert-butoxicarbonilo), C(O)2(fenil(alquilo C1-2)) (tal como benciloxicarbonilo), C(O)NHR43, S(O)2R44, NHS(O)2NHR45, NHC(O)R46, NHC(O)NHR47 o NHS(O)2R48, siempre que ninguno de estos últimos cuatro sustituyentes se encuentre unido a un nitrógeno de anillo; k, l, p y q son, independientemente, 0, 1 ó 2; R20, R22, R24, R26, 27, R29, R31, R33, R37, R40, R51 y R54 son independientemente hidrógeno o alquilo C1-6; R21, R23, R25, R28, R30, R32, R34, R36, R38, R39, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R52, R53, R55, R56 y R57 son, independientemente, alquilo C1-6 (sustituido opcionalmente con halo, hidroxi, alcoxi C1-6, haloalcoxi C1-6, cicloalquilo C3-6, cicloalquenilo C5-6, S(alquilo C1-4), S(O)(alquilo C1-4), S(O)2(alquilo C1-4), heteroarilo, fenilo, heteroariloxi o feniloxi), cicloalquilo C3-7, fenilo o heteroarilo; en los cuales cualquiera de los restos fenilo y heteroarilo inmediatamente precedentes están sustituidos opcionalmente con halo, hidroxi, nitro, S(alquilo C1-4), S(O)(alquilo C1-4), S(O)2(alquilo C1-4), S(O)2NH2, S(O)2NH(alquilo C1-4), S(O)2N(alquilo C1-4)2, ciano, alquilo C1-4, alcoxi C1-4, C(O)NH2, C(O)NH(alquilo C1-4), C(O)N(alquilo C1-4)2, CO2H, CO2(alquilo C1-4), NHC(O)(alquilo C1-4) NHS(O)2(alquilo C1-4), C(O)(alquilo C1-4), CF3 u OCF3; R21, R23, R25, R28, R30, R34, R35, R36, R41, R42, R43, R45, R46, R47, R52, R53, R55 y R57 pueden ser adicionalmente hidrógeno; o una sal aceptable para uso farmacéuticamente del mismo o un solvato del mismo.
ARP030104682A 2002-12-20 2003-12-17 Derivados de piperidina como moduladores del receptor ccr5 AR042628A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0203821A SE0203821D0 (sv) 2002-12-20 2002-12-20 Chemical Compounds
SE0300499A SE0300499D0 (sv) 2003-02-24 2003-02-24 Chemical compounds
SE0301425A SE0301425D0 (sv) 2003-05-15 2003-05-15 Chemical compounds

Publications (1)

Publication Number Publication Date
AR042628A1 true AR042628A1 (es) 2005-06-29

Family

ID=32685861

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104682A AR042628A1 (es) 2002-12-20 2003-12-17 Derivados de piperidina como moduladores del receptor ccr5

Country Status (17)

Country Link
US (1) US20060189650A1 (es)
EP (1) EP1572650A1 (es)
JP (1) JP2006514107A (es)
KR (1) KR20050084424A (es)
AR (1) AR042628A1 (es)
AU (1) AU2003288856B2 (es)
BR (1) BR0317459A (es)
CA (1) CA2508624A1 (es)
CL (1) CL2003002678A1 (es)
CO (1) CO5570665A2 (es)
IS (1) IS7942A (es)
MX (1) MXPA05006381A (es)
NZ (1) NZ540780A (es)
PL (1) PL377768A1 (es)
TW (1) TW200505856A (es)
UY (1) UY28139A1 (es)
WO (1) WO2004056773A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
SE0302090D0 (sv) * 2003-07-16 2003-07-16 Astrazeneca Ab Chemical compounds
JP2007500694A (ja) * 2003-07-31 2007-01-18 アストラゼネカ・アクチエボラーグ Ｃｃｒ５受容体モジュレーターとしてのピペリジン誘導体
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
RU2006146608A (ru) 2004-06-09 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) ОКТАГИДРОПИРРОЛО[3,4-с]-ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ АГЕНТОВ
SE0401657D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
SE0401656D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
KR20080056220A (ko) 2005-10-19 2008-06-20 에프. 호프만-라 로슈 아게 페닐-아세트아마이드 ｎｎｒｔ 저해제
KR101401811B1 (ko) 2006-08-16 2014-05-29 에프. 호프만-라 로슈 아게 비-뉴클레오사이드 역전사효소 저해제
JP2010505767A (ja) * 2006-09-28 2010-02-25 アレテ セラピューティクス， インコーポレイテッド 可溶性エポキシドヒドロラーゼ阻害剤
RU2469032C2 (ru) 2006-12-13 2012-12-10 Ф.Хоффманн-Ля Рош Аг Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы
CN102822163B (zh) 2009-12-23 2016-01-20 艾恩伍德医药品股份有限公司 Crth2调节剂
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2018068296A1 (en) 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
CN113444065A (zh) * 2021-06-29 2021-09-28 浙江得乐康食品股份有限公司 一种莽草酸磺化物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE912759A1 (en) * 1990-08-06 1992-02-12 Smith Kline French Lab Compounds
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
US6432981B1 (en) * 1999-06-11 2002-08-13 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
GB0011838D0 (en) * 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
GB0013060D0 (en) * 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
GB0108046D0 (en) * 2001-03-30 2001-05-23 Astrazeneca Ab Chemical compounds
EP1467986A1 (en) * 2002-01-17 2004-10-20 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors

Also Published As

Publication number Publication date
CO5570665A2 (es) 2005-10-31
CL2003002678A1 (es) 2005-04-22
MXPA05006381A (es) 2005-08-29
TW200505856A (en) 2005-02-16
US20060189650A1 (en) 2006-08-24
JP2006514107A (ja) 2006-04-27
AU2003288856B2 (en) 2006-11-16
IS7942A (is) 2005-07-18
NZ540780A (en) 2008-04-30
EP1572650A1 (en) 2005-09-14
PL377768A1 (pl) 2006-02-20
UY28139A1 (es) 2004-07-30
AU2003288856A1 (en) 2004-07-14
KR20050084424A (ko) 2005-08-26
BR0317459A (pt) 2005-11-16
CA2508624A1 (en) 2004-07-08
WO2004056773A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
AR042628A1 (es) Derivados de piperidina como moduladores del receptor ccr5
AR054809A1 (es) Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa
NO883487D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.
AR064889A1 (es) Derivados de piridopirimidinas, un metodo para su preparacion, una composicion y un producto farmaceutico que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por pde-4
AR032331A1 (es) Derivados heterociclicos, procesos para su preparacion, composiciones farmaceuticas, y usos de dichos derivados en la fabricacion de medicamentos
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR036682A1 (es) Amidas heterociclicas, procedimiento para su preparacion, agentes que los contienen y su utilizacion
AR064345A1 (es) Derivados de 8-oxoadenina
ES2531256T3 (es) Amidas fungicidas
KR930004276A (ko) 치환된 헤테로사이클류
RU2008145708A (ru) Агонисты аденозинового рецептора a3
RU2014129742A (ru) Производные бензолсульфонамида в качестве модуляторов rorc
AR084768A1 (es) Moduladores de la senda de complemento y usos de los mismos
AR045761A1 (es) Derivados de 2-piridona como inhibidores de elastasa de neutrofilos
RU2400483C2 (ru) Пуриновые производные в качестве агонистов рецептора a2a
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
NZ610312A (en) 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors
PE20081344A1 (es) Inhibidores del virus de la hepatitis c
AR078522A1 (es) Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
AR059522A1 (es) Arildihidroisoquinolinas sustituidas con aminoalcoholes, procedimiento para su preparacion y su uso como medicamentos
AR041182A1 (es) Derivados de fenoxipropenilfenilo y su uso como herbicidas
AR071920A1 (es) Compuestos derivados de piridina, proceso para su preparacion, una composicion farmaceutica que lo comprende , metodo para tratar un estado de enfermedad
PE20060692A1 (es) Inhibidores bace
AR037681A1 (es) Antagonistas receptores de adenosina a2a de 5-amino-[1,2,4]-triazol biciclico, composiciones farmaceuticas que los comprenden, el uso de las mismas, solo o en combinacion de los compuestos y otros agentes para la preparacion de medicamentos utiles en el tratamiento de la enfermedad de parkinson y un
AR070345A1 (es) (dihidro ) pirrolo (2,1-a) isoquinolinas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal